Company: RGNX
Filing Date: 2025-04-08
Form Type: DEF 14A
Source: 0000950170-25-052069
Chunk: 74

Company: REGENXBIO Inc.
Filing Date: 2025-04-08
Form: DEF 14A
Chunk 74
---
 date of the 2015 Plan in June of 2025. In addition, as noted above, because a high percentage of our outstanding awards are options with an exercise price far in excess of the current trading value of our stock, it is likely that such awards have lost most or all of their retentive value. Under these circumstances, if we are unable to obtain approval of the 2025 Plan, we may find it increasingly difficult to attract and retain the employees we need to achieve our objectives. In order to attempt to adequately compensate our employees, we may be forced to significantly raise cash compensation in order to address retention concerns. Such action could result in substantial cash expense and potential dilution to the extent we find it necessary to access the capital markets and could have a material adverse effect on our business, results of operations and financial condition.

<div align='center'>53</div>

2025 Equity Incentive Plan

In the following paragraphs we summarize the principal features of the 2025 Plan. This summary is qualified in its entirety by reference to the full text of the 2025 Plan, which is set forth in Appendix A to this proxy statement. Stockholders are urged to read the 2025 Plan in its entirety.

Share Reserve.If stockholders approve the 2025 Plan, an initial total of 5,500,000 shares of stock will be available for issuance under the 2025 Plan, which will be subject to increase by shares that are subject to awards that were granted under the 2015 Plan, are still outstanding on the effective date of the 2025 Plan, and are later forfeited, expire, terminate, or are canceled without the delivery of all shares subject to the award, subject to certain equitable substitutions or adjustments determined by the Administrator. To the extent awards under the 2025 Plan expire, terminate or are canceled, or are settled other than by the delivery of shares of stock, the shares of stock subject to such awards will again become available for issuance under the 2025 Plan, except for the following shares: (i) stock tendered or withheld upon the exercise of an option to cover the exercise price, (ii) stock that is subject to a stock-settled SAR that is not issued upon the net settlement of such SAR, and (iii) stock tendered or withheld to satisfy any tax withholding obligation with respect to an award. In addition, to the extent awards under the 2015 Plan expire, terminate, or are canceled after the effective date of the 202